← Back to Search

Pediatric tympanostomy tube patients for Ear Infection

N/A
Waitlist Available
Led By Ryan Shelton, PhD
Research Sponsored by PhotoniCare, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Children (17 years old or younger) scheduled for tympanostomy tube placement
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-5 minutes
Awards & highlights

Summary

The objective of this study is to evaluate the imaging capabilities and image analysis performance of the OtoSight Middle Ear Scope in pediatric patients undergoing tympanostomy tube placement for otitis media. In this observational study, results of OtoSight imaging will not affect patient standard of care.

Eligible Conditions
  • Ear Infection

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-5 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-5 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
OtoSight imaging exam
Secondary study objectives
Adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pediatric tympanostomy tube patientsExperimental Treatment1 Intervention
Patients diagnosed with otitis media and scheduled for tympanostomy tube placement will be imaged with the OtoSight
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OtoSight Middle Ear Scope
2019
N/A
~110

Find a Location

Who is running the clinical trial?

PhotoniCare, Inc.Lead Sponsor
2 Previous Clinical Trials
888 Total Patients Enrolled
Carle Foundation HospitalOTHER
6 Previous Clinical Trials
611 Total Patients Enrolled
Children's National Health SystemOTHER
9 Previous Clinical Trials
5,002,513 Total Patients Enrolled
~17 spots leftby Oct 2025